All In Biotech

Drug Trial Radar · NCT01211860

Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

A Multiple-Dose Pharmacokinetic Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects With Elevated Fasting Triglyceride Levels

Last checked: Nov 19, 2026Latest source record: Jan 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Oct 2010

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
Essentialis, Inc.Industry
Sponsor type
Industry
Collaborators
Cetero Research, San Antonio
First posted
Sep 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Once a day oral administration with DCCR is the optimal dosing regimen

Conditions

  • Hypertriglyceridmia

Interventions

  • Diazoxide Choline Controlled-Release TabletDrug

    DCCR 290 mg once a day for 10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Steady-state Pharmacokinetic profile of DCCRTime frame: 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cetero

    Fargo, North Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.